Analysts think MTVA stock price could increase by 1271%
Jan 10, 2026, 12:25 PM
-78.03%
What does MTVA do
NeuroBo Pharmaceuticals, based in Cambridge, Massachusetts, develops multi-modal therapies, including DA-1241 for MASH and Type 2 Diabetes, and DA-1726 for obesity. The company went public on August 5, 2016.
6 analysts think MTVA stock price will increase by 1270.70%. The current median analyst target is $113.22 compared to a current stock price of $8.26. The lowest analysts target is $55.55 and the highest analyst target is $219.45.
📡️ Health Care
Price Target
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.